Acciones Advanced Accelerator Application SA(ADR)

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
-	-

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications	03/12/18
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer	12/02/18
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer	01/02/18
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors	26/01/18
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer	22/01/18

Directores	Puesto	Edad	Desde
Caio Kugelmas DFI	Director of Finance/CFO	-	-
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	01/10/19
Ute Simon CTO	Chief Tech/Sci/R&D Officer	-	01/04/20

Administradores	Puesto	Edad	Desde
Frédéric Collet BRD	Director/Board Member	-	01/01/18
Jessica Toepfer BRD	Director/Board Member	-	01/01/18
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	01/10/19

Sector

	Varia. 1 de ene.	Capi.
MERCK KGAA	+5,31 %	70,44 mil M
KYOWA KIRIN CO. LTD.	+10,97 %	8939,13 M
SK BIOPHARMACEUTICALS CO., LTD.	-16,83 %	4750,81 M
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43,48 %	4497,76 M
YUHAN CORPORATION	+3,20 %	3845,87 M
BETTA PHARMACEUTICALS CO., LTD.	-21,36 %	2341,22 M
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29,67 %	2196,26 M
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8,38 %	1963,71 M
SUPERNUS PHARMACEUTICALS, INC.	+3,90 %	1645,88 M